Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

373 trials

NCT05958875
Recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Phase 4 · Austria, Germany, Spain, United Kingdom, Italy · 13 sites
Registry update: 26 Sept 2025
NCT06107764
Recruiting
Cerebellar Modulation of Cognition in Psychosis
Not applicable · United States · 2 sites
Registry update: 20 Aug 2026
NCT06224530
Recruiting
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
Not applicable · United Kingdom · 1 site
Registry update: 5 Aug 2026
NCT06504290
Recruiting
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
Phase 1 · China · 3 sites
Registry update: 14 Aug 2026
NCT06978452
Recruiting
Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories
Not applicable · Canada · 1 site
Registry update: 18 May 2025
NCT06361407
Recruiting
Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia
Not applicable · France · 2 sites
Registry update: 25 Mar 2026
NCT06888726
Recruiting
Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
Not applicable · China · 1 site
Registry update: 4 Jun 2025
NCT06502964
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
Phase 2 · United States · 14 sites
Registry update: 26 Dec 2025
NCT06330467
Recruiting
Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma.
Not applicable · France · 3 sites
Registry update: 24 Apr 2026
NCT06482554
Recruiting
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Phase 3 · United States · 1 site
Registry update: 1 Jul 2024
NCT06191965
Recruiting
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Phase 2/3 · Switzerland, United States · 3 sites
Registry update: 25 Sept 2025
NCT06978894
Recruiting
Predicting Psychotic Relapse Using Speech-Based Early Detection
Not applicable · Canada · 3 sites
Registry update: 18 May 2025
NCT06345963
Recruiting
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
Not applicable · United States · 1 site
Registry update: 7 Jul 2026
NCT06361160
Recruiting
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Not applicable · France · 1 site
Registry update: 21 Sept 2026
NCT05778591
Recruiting
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
Phase 2 · United States · 1 site
Registry update: 28 Apr 2026
NCT06729671
Recruiting
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Not applicable · Ireland · 2 sites
Registry update: 11 Dec 2024
NCT05823532
Recruiting
Anti-Inflammatory Challenge in Schizophrenia
Phase 4 · United States · 2 sites
Registry update: 3 Jun 2026
NCT05814913
Recruiting
Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting
Not applicable · Pakistan · 1 site
Registry update: 12 Dec 2024
NCT06341517
Recruiting
Brain Circuitry Therapeutics for Schizophrenia
Not applicable · Switzerland · 2 sites
Registry update: 19 Nov 2024
NCT06674694
Recruiting
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Phase 1 · China · 1 site
Registry update: 29 Jun 2026

Ordered by registry start date. Freshness and sponsorship never change the order.